Chameleon007
The FDA has granted full approval for AbbVie’s drug (NYSE:ABBV) drug Elahere for the treatment of ovarian cancer.
AbbVie said the drug was approved for the treatment of adult patients with folate receptor-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer treated with up to to three previous therapies.
Elahere, developed by ImmunoGen, received accelerated approval from the FDA in November 2022. The full approval is based on data from a confirmatory Phase 3 study called MIRASOL.
AbbVie acquired ImmunoGen for approximately $10 billion. The deal closed in February.